MDSO - Medidata Solutions, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
91.50
-0.11 (-0.12%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close91.61
Open91.56
Bid91.27 x 1300
Ask94.50 x 800
Day's Range91.34 - 91.64
52 Week Range60.10 - 98.60
Volume946,394
Avg. Volume1,474,968
Market Cap5.715B
Beta (3Y Monthly)1.00
PE Ratio (TTM)127.08
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Medidata (MDSO) Up 0.8% Since Last Earnings Report: Can It Continue?
    Zacks

    Medidata (MDSO) Up 0.8% Since Last Earnings Report: Can It Continue?

    Medidata (MDSO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Chuck Royce's Firm Trims Medidata, Circor Positions
    GuruFocus.com

    Chuck Royce's Firm Trims Medidata, Circor Positions

    Firm's largest sales of the 2nd quarter Continue reading...

  • Medidata (MDSO) Earnings and Revenues Beat Estimates in Q2
    Zacks

    Medidata (MDSO) Earnings and Revenues Beat Estimates in Q2

    Medidata (MDSO) gains from solid segmental contributions in Q2.

  • Earnings Preview: Medidata Solutions (MDSO) Q2 Earnings Expected to Decline
    Zacks

    Earnings Preview: Medidata Solutions (MDSO) Q2 Earnings Expected to Decline

    Medidata (MDSO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Here is What Hedge Funds Think About Medidata Solutions Inc (MDSO)
    Insider Monkey

    Here is What Hedge Funds Think About Medidata Solutions Inc (MDSO)

    The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]

  • Stock Market News For Jun 14, 2019
    Zacks

    Stock Market News For Jun 14, 2019

    Markets closed in the green on Thursday after energy shares rallied following an attack on oil tankers in the Gulf of Oman.

  • Medidata (MDSO) to be Acquired by Dassault for $5.8 Billion
    Zacks

    Medidata (MDSO) to be Acquired by Dassault for $5.8 Billion

    Dassault's acquisition of Medidata (MDSO) to close by 2019-end.

  • TheStreet.com

    Medidata Solutions Dips After $5.8 Billion Sale to France's Dassault Systemes

    shares traded lower Wednesday after it agreed a takeover offer from France's Dassault Systemes SE at a discount to its current market value. Dassault said it would pay $92.25 for each Medidata share in a deal that values the New York-based group at $5.8 billion. "Today marks a significant milestone for the Life Sciences industry and the value of the virtual world to address the complexity of developing personalized medicine and patient-centric experiences," said Dassault CEO Bernard Charles.

  • Dassault to Buy Medidata in $5.7 Billion Shift to Health
    Bloomberg

    Dassault to Buy Medidata in $5.7 Billion Shift to Health

    (Bloomberg) -- French technology company Dassault Systemes SE agreed to buy Medidata Solutions Inc., a software firm that analyzes clinical trials, for $5.7 billion to bolster its offerings to the pharmaceutical industry.The record deal will allow Dassault to offer drugmakers a complete set of services and ride a shift toward personalized medicine, in which research and tools are tailored to individual patient profiles, generating the need to analyze vast amounts of data.Health is becoming a crucial market for Dassault, which also creates 3D design software, said Pascal Daloz, the company’s chief financial officer. Medidata offers clients wearable sensors that help track patients’ health in real life and biomarker analysis to select which ones may best respond to drugs. It estimates that 13 of the top 15 medicines sold last year relied on its technology.“This is by far the largest acquisition we’ve ever made,” Daloz said on a conference call, highlighting Dassault’s interest in the health market.Drugmakers’ CostsThe all-cash transaction values Medidata at $92.25 a share -- 17% more than Medidata’s closing price on April 18, the last trading day before Bloomberg reported Dassault’s interest in the New York-based company. Medidata shares were down 3.5% to $91.45 at 9:59 a.m. in New York. Dassault fell 1.5% to 134.45 euros in Paris.The deal is expected to close in the final quarter of 2019 and start boosting earnings as early as 2020, the companies said in a statement.Drugmakers faced with rising development costs are outsourcing many parts of their research and development efforts, using specialized providers of services and technology.Medidata counts most of the biggest drug companies in the world as customers, according to supply-chain data compiled by Bloomberg. It provides a cloud-based subscription service that helps medical device, diagnostic and pharmaceutical companies manage and analyze clinical trials. Its revenue more than doubled from 2013 to 2018, when it brought in $635.7 million.Dassault, with a market value of 36 billion euros ($41 billion), offers software and services for industries ranging from aerospace and defense to consumer goods. The life sciences business counts many major pharma companies among its clients.The planned acquisition, endorsed by both boards, marks the first time the French company has resorted to external funding, according to Daloz. Dassault will finance the takeover with a 1 billion-euro loan, a 3 billion-euro bridge-to-loan facility and available cash.(Updates with Dassault shares in sixth paragraph.)\--With assistance from Liana Baker, Geraldine Amiel and Marie Mawad.To contact the reporters on this story: Ed Hammond in New York at ehammond12@bloomberg.net;Ruth David in London at rdavid9@bloomberg.net;Manuel Baigorri in Hong Kong at mbaigorri@bloomberg.netTo contact the editors responsible for this story: Elizabeth Fournier at efournier5@bloomberg.net, ;Giles Turner at gturner35@bloomberg.net, Jeff Sutherland, Thomas MulierFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Dow Jones Futures: Elon Musk Touts 'Record' Tesla Quarter; These Stocks Are Big Movers
    Investor's Business Daily

    Dow Jones Futures: Elon Musk Touts 'Record' Tesla Quarter; These Stocks Are Big Movers

    Stock futures: Tesla rose as Elon Musk touted demand at the Tesla shareholder meeting. Medidata, MagnaChip, Dave & Buster's are big movers. Cybersecurity IPO CrowdStrike priced high.

  • TheStreet.com

    Tesla, Medidata, United Tech-Raytheon, Dave & Buster's - 5 Things You Must Know

    U.S. stock futures declined on Wednesday as optimism faded over a near-term trade deal between Washington and Beijing and Wall Street awaited a reading on U.S. inflation. Contracts tied to the Dow Jones Industrial Average fell 71 points, futures for the S&P 500 declined 8.65 points, and Nasdaq futures were down 37 points. Donald Trump said Tuesday he wouldn't agree to a trade deal unless China agrees to four or five "major points" that the president didn't specify.

  • Dassault to Buy Medidata in $5.7 Billion Health Data Push
    Bloomberg

    Dassault to Buy Medidata in $5.7 Billion Health Data Push

    (Bloomberg) -- Dassault Systemes SE, a maker of industrial design software, agreed to buy Medidata Solutions Inc. for $5.7 billion to gain a foothold in the fast-growing market for clinical trial technology.The deal pushes the French company further beyond its design roots into data processing and business analysis. Medidata’s software analyzes pharmaceutical and biotech trials for some of the world’s biggest drugmakers including Sanofi SA, Pfizer Inc. and AstraZeneca Plc.“This is by far the largest acquisition we’ve ever made,” Pascal Daloz, chief financial officer of Dassault Systemes, said on a conference call. He said health is becoming a crucial market for the company, whose customers are mostly in aerospace, defense and consumer goods.The all-cash deal values New York-based Medidata at $92.25 a share, 17% above its closing price on April 18, the last trading day before Bloomberg reported Dassault Systemes’ interest in the company. Medidata stock fell 4.4% to $90.60 in premarket trading.Shares in Dassault Systemes, which has a market value of 36 billion euros ($41 billion) and annual sales of 3.5 billion euros last year, fell as much as 3% before recouping some of the decline to trade down 1% at 11:31 a.m. in Paris.Personalized MedicineMedidata offers clients wearable sensors that help track patient health and biomarker analysis to select which patients may best respond to certain drugs. It estimates that 13 of the top 15 medicines sold last year relied on its technology, as the healthcare industry shifts towards personalized medicine and the targeting of individual patient profiles.President Donald Trump’s protectionist trade agenda hasn’t reduced the appetite of European companies for U.S. takeovers. In fact their appeal has been growing, potentially turning the tables after years in which Europe was mostly a target for U.S. acquirers.French advertising group Publicis Groupe SA announced its biggest ever takeover in April, a $4.4 billion deal for U.S.-based Alliance Data Systems Corp.’s digital marketing unit Epsilon.The Medidata deal is expected to close in the final quarter of 2019 and start boosting earnings as early as 2020, the companies said in a statement. Dassault Systemes will finance it with a 1 billion-euro loan, a 3 billion-euro bridge-to-loan facility and available cash. It’s the first time the French company has resorted to external funding, Daloz said.(Adds Medidata premarket share price in fourth paragraph.)\--With assistance from Liana Baker, Manuel Baigorri, Ruth David, Ed Hammond and Marthe Fourcade.To contact the reporters on this story: Marie Mawad in Paris at mmawad1@bloomberg.net;Geraldine Amiel in Paris at gamiel@bloomberg.netTo contact the editors responsible for this story: Giles Turner at gturner35@bloomberg.net, Thomas Pfeiffer, Frank ConnellyFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Investing.com

    Stocks - Tesla Rises Premarket; Beyond Meat Bounces; BAT Falls

    Investing.com - Stocks in focus in premarket trading on Wednesday:

  • MarketWatch

    Dassault offers to buy Medidata in $5.8 billion deal

    Dassault Systemes SE on Wednesday announced a definite agreement for U.S. technology group Medidata Solutions Inc. , in an agreement valued at $5.8 billion. Under terms of the all-cash deal, the French technology group will offer $92.25 for each share of Medidata, whose shares closed at $94.75 a share on Tuesday. The transaction was unanimously approved by the boards of directors of both companies.

  • Bloomberg

    Dassault Agrees to Buy Medidata in $5.8 Billion Health Deal

    The all-cash deal, which will bolster Dassault’s life-science unit, values Medidata at $92.25 a share. Healthcare has become a core market for Dassault, said Pascal Daloz, Chief Financial Officer, in a call with reporters.

  • Reuters

    UPDATE 3-Dassault Systemes targets life sciences with $5.8 bln Medidata deal

    France's Dassault Systemes moved to build up its life sciences presence with a $5.8 billion cash deal to buy Medidata Solutions, a U.S. firm focused on clinical trials. Dassault Systemes has been doing deals to diversify its technology and software businesses further and its agreed acquisition of Medidata, its largest, follows its purchases of companies including Trace Software and Argosim. Medidata has a market capitalisation of around $5.9 billion, Refinitiv Eikon data shows, while Dassault has a stock market value of around 36 billion euros ($41 billion).

  • Dassault Systemes targets life sciences with $5.8 billion Medidata deal
    Reuters

    Dassault Systemes targets life sciences with $5.8 billion Medidata deal

    France's Dassault Systemes moved to build up its life sciences presence with a $5.8 billion cash deal to buy Medidata Solutions, a U.S. firm focused on clinical trials. Dassault Systemes has been doing deals to diversify its technology and software businesses further and its agreed acquisition of Medidata, its largest, follows its purchases of companies including Trace Software and Argosim. Medidata has a market capitalisation of around $5.9 billion, Refinitiv Eikon data shows, while Dassault has a stock market value of around 36 billion euros ($41 billion).

  • Is Medidata Solutions, Inc. (NASDAQ:MDSO) As Strong As Its Balance Sheet Indicates?
    Simply Wall St.

    Is Medidata Solutions, Inc. (NASDAQ:MDSO) As Strong As Its Balance Sheet Indicates?

    Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Medidata Solutions...

  • Here's Why You Should Hold on to Medidata (MDSO) Stock Now
    Zacks

    Here's Why You Should Hold on to Medidata (MDSO) Stock Now

    Medidata Solutions (MDSO) continues to benefit from solid R&D focus, Rave Genomics platform and cloud-based services. However, stiff competition remains a concern.

  • Medidata (MDSO) Down 1.9% Since Last Earnings Report: Can It Rebound?
    Zacks

    Medidata (MDSO) Down 1.9% Since Last Earnings Report: Can It Rebound?

    Medidata (MDSO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Markit

    See what the IHS Markit Score report has to say about Medidata Solutions Inc.

    Medidata Solutions Inc NASDAQ/NGS:MDSOView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is moderate and declining Bearish sentimentShort interest | PositiveShort interest is moderate for MDSO with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on May 20. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $1.46 billion over the last one-month into ETFs that hold MDSO are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Technology sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Thomson Reuters StreetEvents

    Edited Transcript of MDSO earnings conference call or presentation 30-Apr-19 12:00pm GMT

    Q1 2019 Medidata Solutions Inc Earnings Call

  • Medidata Solutions Near 10-Week Line
    Investor's Business Daily Video

    Medidata Solutions Near 10-Week Line

    This was a tight trade near 10-week line. The base shows a 98.70 buy point.